Inotersen

Drug Profile

Inotersen

Alternative Names: GSK 2998728; IONIS TTRRx; ISIS 420915; ISIS-GSK1Rx; ISIS-TTRRx

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer GlaxoSmithKline; Indiana University School of Medicine; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Antisense RNA modulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyloid polyneuropathy
  • Phase II Amyloidosis; Cardiomyopathies

Most Recent Events

  • 11 Aug 2017 Ionis completes a phase III trial for Amyloid polyneuropathy in USA, Argentina, Brazil, France, Germany, Italy, New Zealand, Portugal, Spain and the United Kingdom (NCT01737398)
  • 11 Aug 2017 Ionis Pharmaceuticals announces intention to submit MAA to the EMA for Amyloid polyneuropathy by the end of 2017
  • 11 Aug 2017 GlaxoSmithKline declines options to licence inotersen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top